(Q28069603)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

review article

1 reference

title

Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

19 December 2019

1 reference

19 December 2019

pituitary-dependent Cushing's disease

1 reference

19 December 2019

1 reference

19 December 2019

Pasireotide

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

1 reference

1 October 2016

8 references

14 February 2019

13 March 2019

24 March 2019

25 April 2019

17 November 2019

20 November 2019

19 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

9 references

14 February 2019

13 March 2019

24 March 2019

25 April 2019

17 November 2019

20 November 2019

19 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

19

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

536-543

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

18 March 2020

copyright license

7 references

14 February 2019

13 March 2019

24 March 2019

25 April 2019

17 November 2019

20 November 2019

on focus list of Wikimedia project

19 December 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11102-016-0734-1

0 references

cites work

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Prevalence of diabetes mellitus in patients with acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

The burden of Cushing's disease: clinical and health-related quality of life aspects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

The pathophysiological consequences of somatostatin receptor internalization and resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996868

Acromegaly: an endocrine society clinical practice guideline

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-016-0734-1

Effective long-term treatment of Cushing's disease with pasireotide: a case report

21 January 2018

1 reference

12 December 2020

Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

1 reference

12 December 2020

Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse

1 reference

12 December 2020

10.1007/S11102-016-0734-1

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27405306%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2 references